The effects of estrogen on serum level and hepatocyte expression of PCSK9

Metabolism: Clinical and Experimental

Volumn 64, Issue 4, 2015, Pages 554-560

  Guo, Wen ^a,b   Fu, Jinxiang ^a   Chen, Xiaoli ^a   Gao, Beibei ^a   Fu, Zhenzhen ^a   Fan, Hongqi ^a   Cui, Qin ^c   Zhu, Xiaohui ^a   Zhao, Yang ^d   Yang, Tao ^a   Fan, Daping ^e   Zhou, Hongwen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Governmental Hospital   (China)

^c Tongling People's Hospital   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Low density lipoprotein cholesterol (LDL C); Low density lipoprotein receptor (LDLR); Proprotein convertase subtilisin kexin type 9 (PCSK9)

Indexed keywords

CHOLESTEROL; ESTRADIOL; ESTROGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIVER CELL; LUTEAL PHASE; MENSTRUAL CYCLE; MIDDLE AGED; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; BLOOD; CELL CULTURE; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; MENOPAUSE; METABOLISM; MOUSE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; ESTRADIOL; FEMALE; HEP G2 CELLS; HEPATOCYTES; HUMANS; MENOPAUSE; MICE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 84923602966     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.01.009     Document Type: Article

References (21)

1. M. Tamada, S. Makita, A. Abiko, Y. Naganuma, M. Nagai, and M. Nakamura Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis Metabolism 59 2010 653 657
2. W.B. Kannel, M.C. Hjortland, P.M. McNamara, and T. Gordon Menopause and risk of cardiovascular disease: the Framingham study Ann Intern Med 85 1976 447 452
3. E.J. Schaefer, D.M. Foster, L.A. Zech, F.T. Lindgren, H.J. Brewer, and R.I. Levy The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females J Clin Endocrinol Metab 57 1983 262 267
4. E.E. Windler, P.T. Kovanen, Y.S. Chao, M.S. Brown, R.J. Havel, and J.L. Goldstein The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E J Biol Chem 255 1980 10464 10471
5. H. Pandey, A. Arjuman, K.K. Roy, and N.C. Chandra Reciprocal coordination of a combination oral contraceptive containing desogestrel + ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells Contraception 84 2011 e43 e49
6. C.J. Lee, Y.H. Lee, S.W. Park, K.J. Kim, S. Park, and J.C. Youn Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects Metabolism 62 2013 845 850
7. F. Lalanne, G. Lambert, M.J. Amar, M. Chetiveaux, Y. Zair, and A.L. Jarnoux Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells J Lipid Res 46 2005 1312 1319
8. L. Palacios, L. Grandoso, N. Cuevas, E. Olano-Martin, A. Martinez, and D. Tejedor Molecular characterization of familial hypercholesterolemia in Spain Atherosclerosis 221 2012 137 142
9. J.C. Cohen, E. Boerwinkle, T.J. Mosley, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
10. Q. Cui, X. Ju, T. Yang, M. Zhang, W. Tang, and Q. Chen Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population Atherosclerosis 213 2010 632 636
11. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels J Clin Endocrinol Metab 94 2009 2537 2543
12. D. Grady, S.M. Rubin, D.B. Petitti, C.S. Fox, D. Black, and B. Ettinger Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016 1037
13. B.W. Walsh, I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F.M. Sacks Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins N Engl J Med 325 1991 1196 1204
14. M.E. Mendelsohn Protective effects of estrogen on the cardiovascular system Am J Cardiol 89 2002 12E 17E
15. N.G. Seidah PCSK9 as a therapeutic target of dyslipidemia Expert Opin Ther Targets 13 2009 19 28
16. B. Gencer, N. Rodondi, and F. Mach PCSK9 inhibitors: emerging treatment to lower cholesterol? Rev Med Suisse 10 2014 539 542 [544]
17. E.A. Stein, R.P. Giugliano, M.J. Koren, F.J. Raal, E.M. Roth, and R. Weiss Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J 35 2014 2249 2259
18. S.E. Ngo, N.A. Chapados, and J.M. Lavoie LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training Horm Metab Res 46 2014 550 555
19. L. Persson, C. Galman, B. Angelin, and M. Rudling Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors Endocrinology 150 2009 1140 1146
20. L. Persson, P. Henriksson, E. Westerlund, O. Hovatta, B. Angelin, and M. Rudling Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women Arterioscler Thromb Vasc Biol 32 2012 810 814
21. M.A. Driancourt, P. Cox, S. Rubion, G. Harnois-Milon, B. Kemp, and N.M. Soede Induction of an LH surge and ovulation by buserelin (as Receptal) allows breeding of weaned sows with a single fixed-time insemination Theriogenology 80 2013 391 399